Cyclacel Pharmaceuticals, Inc. Logo

Cyclacel Pharmaceuticals, Inc.

CYCC

(1.2)
Stock Price

0,41 USD

-214.54% ROA

2923.81% ROE

-0.09x PER

Market Cap.

1.757.038,00 USD

0.5% DER

0% Yield

-15508.05% NPM

Cyclacel Pharmaceuticals, Inc. Stock Analysis

Cyclacel Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cyclacel Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cyclacel Pharmaceuticals, Inc. Price Chart

Chart

Combination chart with 3 data series.
The chart has 2 X axes displaying Time, and navigator-x-axis.
The chart has 3 Y axes displaying values, values, and navigator-y-axis.
View 1 month1mView 3 months3mView 6 months6mView year to dateYTDView 1 year1yView allAllHighcharts.com
End of interactive chart.

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cyclacel Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.04
Net Income per Share
-9.73
Price to Earning Ratio
-0.09x
Price To Sales Ratio
21.96x
POCF Ratio
-0.14
PFCF Ratio
-0.15
Price to Book Ratio
1.61
EV to Sales
-52.97
EV Over EBITDA
0.17
EV to Operating CashFlow
0.37
EV to FreeCashFlow
0.37
Earnings Yield
-10.94
FreeCashFlow Yield
-6.55
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
11.01
Graham NetNet
-0.26

Income Statement Metrics

Net Income per Share
-9.73
Income Quality
0.66
ROE
-18.74
Return On Assets
-2.13
Return On Capital Employed
19.44
Net Income per EBT
0.6
EBT Per Ebit
1.02
Ebit per Revenue
-254.88
Effective Tax Rate
0.3

Margins

Sales, General, & Administrative to Revenue
83.81
Research & Developement to Revenue
221.03
Stock Based Compensation to Revenue
13.81
Gross Profit Margin
0.7
Operating Profit Margin
-254.88
Pretax Profit Margin
-258.84
Net Profit Margin
-155.08

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.01
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-6.38
Free CashFlow per Share
-6.38
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-17.39
Return on Tangible Assets
-2.15
Days Sales Outstanding
4443.88
Days Payables Outstanding
91077.11
Days of Inventory on Hand
0
Receivables Turnover
0.08
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
3,32
Book Value per Share
0,55
Tangible Book Value per Share
0.55
Shareholders Equity per Share
0.55
Interest Debt per Share
0.08
Debt to Equity
0.01
Debt to Assets
0
Net Debt to EBITDA
0.25
Current Ratio
1.07
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
591000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cyclacel Pharmaceuticals, Inc. Profile

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

CEO
Mr. Spiro George Rombotis
Employee
12
Address
200 Connell Drive
Berkeley Heights, 07922

Cyclacel Pharmaceuticals, Inc. Executives & BODs

Cyclacel Pharmaceuticals, Inc. Competitors

Eliem Therapeutics, Inc. Logo
Eliem Therapeutics, Inc.

ELYM

(1.8)
Ikena Oncology, Inc. Logo
Ikena Oncology, Inc.

IKNA

(1.2)
Ovid Therapeutics Inc. Logo
Ovid Therapeutics Inc.

OVID

(1.2)
Connect Biopharma Holdings Limited Logo
Connect Biopharma Holdings Limited

CNTB

(1.8)
Edgewise Therapeutics, Inc. Logo
Edgewise Therapeutics, Inc.

EWTX

(1.0)
Rezolute, Inc. Logo
Rezolute, Inc.

RZLT

(1.2)
Cyteir Therapeutics, Inc. Logo
Cyteir Therapeutics, Inc.

CYT

(1.2)
XOMA Corporation Logo
XOMA Corporation

XOMAO

(1.2)
Protagenic Therapeutics, Inc. Logo
Protagenic Therapeutics, Inc.

PTIX

(1.2)
Tempest Therapeutics, Inc. Logo
Tempest Therapeutics, Inc.

TPST

(0.2)
OncoVista Innovative Therapies, Inc. Logo
OncoVista Innovative Therapies, Inc.

OVIT

(0.0)
Neurobiological Technologies, Inc. Logo
Neurobiological Technologies, Inc.

NTII

(0.0)
Polydex Pharmaceuticals Limited Logo
Polydex Pharmaceuticals Limited

POLXF

(0.8)
Catalyst Biosciences, Inc. Logo
Catalyst Biosciences, Inc.

CBIO

(1.8)
Moleculin Biotech, Inc. Logo
Moleculin Biotech, Inc.

MBRX

(1.2)
Pulmatrix, Inc. Logo
Pulmatrix, Inc.

PULM

(1.8)
Akari Therapeutics, Plc Logo
Akari Therapeutics, Plc

AKTX

(0.5)
NextCure, Inc. Logo
NextCure, Inc.

NXTC

(1.2)
CytomX Therapeutics, Inc. Logo
CytomX Therapeutics, Inc.

CTMX

(1.8)
Neoleukin Therapeutics, Inc. Logo
Neoleukin Therapeutics, Inc.

NLTX

(1.5)
Spero Therapeutics, Inc. Logo
Spero Therapeutics, Inc.

SPRO

(1.5)
Assembly Biosciences, Inc. Logo
Assembly Biosciences, Inc.

ASMB

(1.8)